Compare

Roman DBDR Acquisition Corp. II vs Archimedes Tech SPAC Partners II Co. vs Evolution Global Acquisition Corp vs Drugs Made In America Acquisition Corp.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Roman DBDR Acquisition Corp. II DRDB	Archimedes Tech SPAC Partners II Co. ATII	Evolution Global Acquisition Corp EVOX	Drugs Made In America Acquisition Corp. DMAA
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	n/a	n/a
Revenue growth (YoY)	n/a	n/a	n/a	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	n/a	n/a
Net margin	n/a	n/a	n/a	n/a
Net income	$7.74M	$7.99M	n/a	$5.94M
EPS (Diluted)	n/a	n/a	n/a	n/a
Operating cash flow	-$1.29M	-$739.0K	n/a	-$539.2K
Free cash flow	n/a	n/a	n/a	n/a
Cash & equivalents	$183.0K	$1.36M	$1.12M	n/a
Total assets	$241.51M	$241.35M	$242.47M	$239.92M
Total liabilities	$1.10M	$8.19M	$9.77M	$7.28M
Shareholders' equity	-$778.1K	-$6.70M	-$8.50M	-$7.26M
Return on year-end equity	n/a	n/a	n/a	n/a
Shares outstanding	n/a	6.59M	n/a	10.72M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Roman DBDR Acquisition Corp. II	Archimedes Tech SPAC Partners II Co.	Evolution Global Acquisition Corp	Drugs Made In America Acquisition Corp.
Latest	n/a	n/a	n/a	n/a
1 year earlier	n/a	n/a	n/a	n/a
2 years earlier	n/a	n/a	n/a	n/a
3 years earlier	n/a	n/a	n/a	n/a
4 years earlier	n/a	n/a	n/a	n/a